Analog Devices Inc (ANL.HA)
| Previous Close | 180.20 |
| Open | 183.86 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 183.86 - 183.86 |
| 52 Week Range | 145.90 - 190.08 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Analog Devices, Inc. to Report Second Quarter Fiscal Year 2024 Financial Results on Wednesday, May 22, 2024
Analog Devices, Inc. (Nasdaq: ADI) today announced it will release financial results for the second quarter fiscal year 2024 at 7:00 a.m. Eastern time on Wednesday, May 22, 2024. Following the press release, the Company will host a conference call at 10:00 a.m. Eastern time, the same day. Vincent Roche, Chief Executive Officer and Chair, Richard Puccio, Executive Vice President and Chief Financial Officer, and Michael Lucarelli, Vice President of Investor Relations and FP&A will discuss ADI's re
- PR Newswire
ADI and the BMW Group Join Forces to Provide Industry-Leading 10MB Ethernet for Automotive, Enabling Software-Defined Vehicles
Analog Devices, Inc. (Nasdaq: ADI) and the BMW Group (Nasdaq: BMWYY) today announced an early adoption of E²B™, ADI's 10BASE-T1S Ethernet to the Edge bus technology within the automotive industry. Automotive Ethernet connectivity is a key enabler of new, zonal architectures in automotive design and supports automotive megatrends such as software-defined vehicles. The BMW Group will be a leading original equipment manufacturer (OEM) to implement the technology, leveraging ADI's E²B for their ambi
- PR Newswire
ADI Announces U.S. FDA 510(k) Clearance and the Commercial Launch of Sensinel by Analog Devices™ Cardiopulmonary Management (CPM) System
Analog Devices, Inc. (Nasdaq: ADI) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the commercial launch of the Sensinel™ Cardiopulmonary Management (CPM) System. The compact wearable device is a non-invasive, remote management system that captures cardiopulmonary measurements for chronic disease management such as heart failure. It is the first FDA clearance the company has received in its 59-year history.
